

Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that members of its executive management team will present at the following upcoming conferences:

Baird's 2013 Health Care Conference — Dan Passeri, Chief Executive Officer, will present on Wednesday, September 11, 2013 at 8:30 a.m. ET in New York City. A corresponding webcast of this presentation can be accessed by visiting:

<http://wsw.com/webcast/baird35/CRIS>

Stifel Healthcare Conference 2013 — Ali Fattaey, President and Chief Operating Officer, will present on Thursday, September 12, 2013 at 3:15 p.m. ET in Boston. A corresponding audio webcast can be accessed by visiting:

<http://www.veracast.com/webcasts/stifel/healthcare2013/32212532775.cfm>

Both presentations will be held using a "fireside chat" format in which Mr. Passeri or Dr. Fattaey will provide a brief overview of the Company's business strategy and pipeline of targeted cancer drug candidates, after which an equity analyst will moderate a question and answer session.

The presentations will be archived shortly after the live events and available for 30 days following the conference. In addition, they will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Vice President, Corporate Strategy and Investor Relations

617-503-6605

mmohindru@curis.com

Michael P. Gray

Chief Financial Officer

Curis, Inc.

617-503-6632

mgray@curis.com

<https://investors.curis.com/press-releases?item=136>